BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug pricing

  CMS Prepares for Third Cycle of Drug Negotiations as Trump Intensifies Push To Lower Prices

  The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in 2028.

  May 13, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Funding

  Azafaros Raises $150M To Target Rare Neuro-Metabolic Diseases

  Azafaros will use the Series B haul to push lead asset nizubaglustat into late-stage studies for Niemann-Pick disease Type C and GM1/GM2 gangliosidoses later this year.

  May 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Bayer’s Continued Restructuring Claims 2,000 Jobs and Thins Management Layers

  Meanwhile, Bayer CEO Bill Anderson said Donald Trump’s Most Favored Nations policy could present an opportunity for European countries to make sure they are also funding their “fair share” of biopharma innovation.

  May 13, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Manufacturing

  Roche’s Genentech Earmarks $700M for North Carolina Plant as Billion-Dollar US Pledge Hangs in Balance

  The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that could change if certain yet-unspecified policies are implemented that could “harm our industry’s ability to operate and innovate in America.”

  May 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pharmacy benefit managers

  Trump’s Most Favored Nation Policy Sparks PBM Selloff

  The Most Favored Nation directive would allow drugmakers to directly sell their products to patients at a lower cost, cutting out what President Donald Trump called “the middlemen.”

  May 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  C-suite

  Galapagos Takes Dramatic U-Turn, Ditching Spinout Plan, Cell Therapy and CEO Stoffels

  It’s another wild twist in the story of Galapagos, a company that has been around for more than 25 years but has yet to get a therapy approved.

  May 13, 2025

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Layoffs

  The 5 Largest Biopharma Layoffs of Q1 2025: Updated

  The number of employees laid off increased year over year during the first quarter. BioSpace recaps the five largest rounds of layoffs, which included BMS and Novartis cuts.

  May 13, 2025

   · 

  5 min read

   · 

  Angela Gabriel
• Press Releases

  Surgery Partners, Inc. Announces First Quarter 2025 Results; Reaffirms Full Year 2025 Guidance

  May 13, 2025

   · 

  16 min read
• Press Releases

  Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value

  May 13, 2025

   · 

  9 min read
• Press Releases

  Roche and Genentech Announce New North Carolina Manufacturing Facility

  May 13, 2025

   · 

  4 min read